Pages that link to "Q39028178"

The following pages link to Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. (Q39028178):

Displaying 30 items.

• Spotlight on ixazomib: potential in the treatment of multiple myeloma (Q26774440) (← links)
• KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism (Q27853300) (← links)
• Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling (Q28082335) (← links)
• An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma (Q33418098) (← links)
• The effects of proteasome inhibitors on bone remodeling in multiple myeloma (Q33918020) (← links)
• Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics (Q34038854) (← links)
• CCR 20th anniversary commentary: In the beginning, there was PS-341. (Q35146095) (← links)
• Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy (Q35912293) (← links)
• Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma (Q36178810) (← links)
• Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment (Q37298880) (← links)
• Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis (Q37689041) (← links)
• The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma (Q37697141) (← links)
• The osteoblastic niche in the context of multiple myeloma (Q38271428) (← links)
• The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. (Q38400460) (← links)
• Ixazomib for the treatment of multiple myeloma. (Q38542172) (← links)
• Oral ixazomib maintenance therapy in multiple myeloma. (Q38640514) (← links)
• Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma (Q38672091) (← links)
• Ixazomib: First Global Approval (Q38723292) (← links)
• Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry (Q38725959) (← links)
• Molecular mechanisms, current management and next generation therapy in myeloma bone disease. (Q38749233) (← links)
• Bone metastasis: the importance of the neighbourhood. (Q38843253) (← links)
• Safety of ixazomib for the treatment of multiple myeloma (Q39404809) (← links)
• Ixazomib enhances parathyroid hormone-induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor (Q41001463) (← links)
• The Proteasome and Myeloma-Associated Bone Disease (Q47696279) (← links)
• Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma (Q47784917) (← links)
• The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. (Q47873839) (← links)
• Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway (Q48522982) (← links)
• New agents in the Treatment of Myeloma Bone Disease (Q50323850) (← links)
• Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells (Q89529241) (← links)
• Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management (Q92772115) (← links)